A 39-year-old man with sudden onset of chest pain

Cleveland Clinic Journal of Medicine

Volumn 72, Issue 11, 2005, Pages 1050-1056

  Sunkureddi, Prashanth R ^a   Gonzalez, Emilio B ^a   Washington, Rickey ^b   Salazar, Andres ^b   Douglass, Paul ^b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b ATLANTA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTINUCLEAR ANTIBODY; DOUBLE STRANDED DNA ANTIBODY; FOLIC ACID; GLYCERYL TRINITRATE; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MORPHINE; PREDNISOLONE; RNA ANTIBODY; SM ANTIBODY; ANTIRHEUMATIC AGENT; GLUCOCORTICOID; PREDNISONE;

ADULT; CASE REPORT; ECHOCARDIOGRAPHY; HEART CATHETERIZATION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; LABORATORY TEST; MALE; PATIENT TRANSPORT; PERICARDITIS; PHYSICAL EXAMINATION; REVIEW; ST SEGMENT ELEVATION; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX PAIN; TRANSIENT ISCHEMIC ATTACK; ACUTE DISEASE; ARTICLE; DIFFERENTIAL DIAGNOSIS; DRUG COMBINATION; ELECTROCARDIOGRAPHY; PLEURISY;

ACUTE DISEASE; ADULT; ANTIRHEUMATIC AGENTS; CHEST PAIN; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; GLUCOCORTICOIDS; HUMANS; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PERICARDITIS; PLEURISY; PREDNISONE;

EID: 33644645387     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.72.11.1050     Document Type: Review

References (49)

1. Pisetky DS. Systemic lupus erythematosus. In: Klippel JH, Crofford LJ, Stone JH, Weyand CM, editors. Primer on the Rheumatic Diseases. 12th ed. Atlanta, Ga: Arthritis Foundation; 2001:329-346.
2. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271-1277.
3. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40:1725.
4. Roberts WC, High ST. The heart in systemic lupus erythematosus. Curr Probl Cardiol 1999; 24:1-56.
5. Moder KG, Miller TM, Tazelaar HD. Cardiac involvement in systemic lupus erythematosus. Mayo Clin Proc 1999; 74:275-284.
6. Estes D, Christian CL. The natural history of systemic lupus erythematosus by prospective analysis. Medicine (Baltimore) 1971; 50:85-95.
7. Doherty NE, Siegel RJ. Cardiovascular manifestations of systemic lupus erythematosus. Am Heart J 1985; 110:1257-1265.
8. Mandell BF. Cardiovascular involvement in systemic lupus erythematosus. Semin Arthritis Rheum 1987; 17:126-141.
9. Kao AH, Manzi S. How to manage patients with cardiopulmonary disease? Best Pract Res Clin Rheumatol 2002; 16:211-227.
10. Badui E, Garcia-Rubi D, Robles E, et al. Cardiovascular manifestations in systemic lupus erythematosus. Prospective study of 100 patients. Angiology 1985; 36:431-441.
11. Fairfax MJ, Osborn TG, Williams GA, Tsai CC, Moore TL. Endomyocardial biopsy in patients with systemic lupus erythematosus. J Rheumatol 1988; 15:593-596.
12. Morguet AJ, Sandrock D, Stille-Siegener M, Figulla HR. Indium-111-antimyosin Fab imaging to demonstrate myocardial involvement in systemic lupus erythematosus. J Nucl Med 1995; 36:1432-1435.
13. Winslow TM, Ossipov MA, Fazio GP, Foster E, Simonson JS, Schiller NB. The left ventricle in systemic lupus erythematosus: initial observations and a five-year follow-up in a university medical center population. Am Heart J 1993; 125:1117-1122.
14. Libman E, Sacks B. A hitherto undescribed form of valvular and mural endocarditis. Arch Intern Med 1924; 33:701-737.
15. Bijl M, Brouwer J, Kallenberg GG. Cardiac abnormalities in SLE: pancarditis. Lupus 2000; 9:236-240.
16. Galve E, Candell-Riera J, Pigrau C, Permanyer-Miralda G, Garcia-Del-Castillo H, Soler-Soler J. Prevalence, morphologic types, and evolution of cardiac valvular disease in systemic lupus erythematosus. N Engl J Med 1988; 319:817-823.
17. Roldan CA, Shively BK, Crawford MH. An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus. N Engl J Med 1996; 335:1424-1430.
18. Asherson RA, Hughes GR. The expanding spectrum of Libman Sacks endocarditis: the role of antiphospholipid antibodies. Clin Exp Rheumatol 1989; 7:225-228.
19. Leung WH, Wong KL, Lau CP, Wong CK, Liu HW. Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus. Am J Med 1990; 89:411-419.
20. Reisner SA, Brenner B. Haim N, Edoute Y, Markiewicz W. Echocardiography in nonbacterial thrombotic endocarditis: from autopsy to clinical entity. J Am Soc Echocardiogr 2000; 13:876-881.
21. Ziporen L, Goldberg I, Arad M, et al. Libman-Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves. Lupus 1996; 5:196-205.
22. Gleason CB, Stoddard MF, Wagner SG, Longaker RA, Pierangeli S, Harris EN. A comparison of cardiac valvular involvement in the primary antiphospholipid syndrome versus anticardiolipin-negative systemic lupus erythematosus. Am Heart J 1993; 125:1123-1129.
23. Asanuma Y, Oeser A, Shintani AK, et al. Premature coronary artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349:2407-2415.
24. Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349:2399-2406.
25. Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42:338-346.
26. Sturfelt G, Eskilsson J, Nived O, Truedsson L, Valind S. Cardiovascular disease in systemic lupus erythematosus. A study of 75 patients from a defined population. Medicine (Baltimore) 1992; 71:216-223.
27. Sun SS, Shiau YC, Tsai SC, Lin CC, Kao A, Lee CC. The role of technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography (SPECT) in the detection of cardiovascular involvement in systemic lupus erythematosus patients with non-specific chest complaints. Rheumatology (Oxford) 2001; 40:1106-1111.
28. Petri M, Spence D, Bone LR, Hochberg MC. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine (Baltimore) 1992; 71:291-302.
29. Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996; 348:1120-1124.
30. Maxwell SR, Moots RJ, Kendall MJ. Corticosteroids: do they damage the cardiovascular system? Postgrad Med J 1994; 70:863-870.
31. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44:2331-2337.
32. Hughes GR. Immunology, lupus and atheroma. Lupus 2000; 9:159-160.
33. Pineau CA, Gladman DD, Ibanez D, Urowitz MB. Lupus disease activity and coronary artery disease [abstract]. Arthritis Rheum 2001; 44:S287.
34. Vaarala O. Autoantibodies to modified LDLs and other phospholipid-protein complexes as markers of cardiovascular diseases. J Intern Med 2000; 247:381-384.
35. Reichlin M, Fesmire J, Quintero-Del-Rio AI, Wolfson-Reichlin M. Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis Rheum 2002; 46:2957-2963.
36. Salonen JT, Yla-Herttuala S, Yamamoto R, et al. Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet 1992; 339:883-887.
37. Puurunen M, Manttari M, Manninen V, et al. Antibody against oxidized low-density lipoprotein predicting myocardial infarction (erratum in Arch Intern Med 1995; 155:817). Arch Intern Med 1994; 154:2605-2609.
38. Karrar A, Sequeira W, Block JA. Coronary artery disease in systemic lupus erythematosus: a review of the literature. Semin Arthritis Rheum 2001; 30:436-443.
39. Alarcon-Segovia D, Deleze M, Oria CV, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine (Baltimore) 1989; 68:353-365.
40. Ohlenschlaeger T, Garred P, Madsen HO, Jacobsen S. Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus. N Engl J Med 2004; 351:260-267.
41. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2002; 25:213-229.
42. Espinola R, Pierangeli S, Gharavi AE, Harris EN. Hydroxychloroquine reverses platelet activation induced by human lgG antiphospholipid antibodies. Thromb Haemost 2002; 87:518-22.
43. Petri M, Lakatta C, Magder L, Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 1994; 96:254-259.
44. James TN, Rupe CE, Monto RW. Pathology of the cardiac conduction system in systemic lupus erythematosus. Ann Intern Med 1965; 63:402-410.
45. Bharati S, de la Fuente DJ, Kallen RJ, Freij Y, Lev M. Conduction system in systemic lupus erythematosus with atrioventricular block. Am J Cardiol 1975; 35:299-304.
46. Lagana B, Tubani L, Maffeo N, et al. Heart rate variability and cardiac autonomic function in systemic lupus erythematosus. Lupus 1996; 5:49-55.
47. Stein KS, McFarlane IC, Goldberg N, Ginzler EM. Heart rate variability in patients with systemic lupus erythematosus. Lupus 1996; 5:44-48.
48. Hogarth MB, Judd L, Mathias CJ, Ritchie J, Stephens D, Rees RG. Cardiovascular autonomic function in systemic lupus erythematosus. Lupus 2002; 11:308-312.
49. Silverman ED, Laxer RM. Neonatal lupus erythematosus. Rheum Dis Clin North Am 1997; 23:599-618.